• Yuki Kondo, Masaru Ishida, Takenori Ishisone, Masanobu Niiyama, Takuya Osaki, Yuki Matsumoto, Yuko Maegawa, Kenta Sasaki, Ryo Ninomiya, Yuji Takahashi, Yu Ishikawa, Takumi Kimura, Yudai Shimoda, Munetaka Morikawa, Hidenori Saito, Tomonori Itoh, and Yoshihiro Morino.
• Division of Cardiology, Department of Internal Medicine, Iwate Medical University Hospital, Japan.
• Intern. Med. 2024 Nov 15; 63 (22): 303130383031-3038.

AbstractObjective We aimed to reveal detailed on-treatment lipid profiles, lipid-related surrogate markers, and factors predicting failure to achieve the guideline-recommended lipid management goal following guideline-recommended statin treatment in Japanese patients with acute myocardial infarction (AMI). Methods Sixty AMI patients who underwent coronary intervention and had received rosuvastatin 10 mg/day since the start of their hospitalization were assessed for on-treatment lipid-related profiles, including high-sensitivity C-reactive protein, small dense low-density lipoprotein cholesterol (sd LDL-C), and lipoprotein (a), at the 12-week follow-up. Patients who failed to achieve the guideline-recommended lipid management at 12 weeks were defined as the "unachieved group." Univariate and multivariate logistic regression analyses were performed to evaluate the predictors of inclusion in the unachieved group after high-dose statin treatment. Results Despite the use of high-dose rosuvastatin, 61.7% of the enrolled AMI patients were included in the unachieved group. In addition, the unachieved group had higher sd LDL-C and lipoprotein (a) levels than the achieved group. Logistic regression analyses demonstrated that low baseline high-density lipoprotein cholesterol (HDL-C) levels and the absence of diabetes were predictors of inclusion in the unachieved group. Conclusion More than half of the Japanese AMI patients treated with rosuvastatin 10 mg/day did not achieve the guideline-recommended goal of lipid management and still had lipid-related residual risk at 12 weeks. Particular attention should be paid to patients with low baseline HDL-C levels and those without diabetes with regard to their on-treatment lipid profiles.

27 keywords...

hide…